Edwards Lifesciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. 

CEO
Bernard J. Zovighian
CEOBernard J. Zovighian
Employees
16,000
Employees16,000
Headquarters
Irvine, California
HeadquartersIrvine, California
Founded
1958
Founded1958
Employees
16,000
Employees16,000

EW Key Statistics

Market cap
49.43B
Market cap49.43B
Price-Earnings ratio
47.02
Price-Earnings ratio47.02
Dividend yield
Dividend yield
Average volume
5.06M
Average volume5.06M
High today
High today
Low today
Low today
Open price
$86.11
Open price$86.11
Volume
0.00
Volume0.00
52 Week high
$87.89
52 Week high$87.89
52 Week low
$65.94
52 Week low$65.94

Stock Snapshot

As of today, Edwards Lifesciences(EW) shares are valued at $84.86. The company's market cap stands at 49.43B, with a P/E ratio of 47.02.

Edwards Lifesciences(EW) stock opened on 2026-03-12 at $86.11. The price climbed to — and dipped to —.

Edwards Lifesciences(EW) shares are trading with a volume of 0, against a daily average of 5.06M.

In the last year, Edwards Lifesciences(EW) shares hit a 52-week high of $87.89 and a 52-week low of $65.94.

In the last year, Edwards Lifesciences(EW) shares hit a 52-week high of $87.89 and a 52-week low of $65.94.

EW News

Simply Wall St 3h
A Look At Edwards Lifesciences Valuation As It Exits Critical Care To Focus On Core Heart Therapies

Edwards Lifesciences (EW) has been back in focus after moving to sell its critical care unit and to concentrate on areas such as asymptomatic aortic stenosis an...

A Look At Edwards Lifesciences Valuation As It Exits Critical Care To Focus On Core Heart Therapies
Simply Wall St 2d
Edwards’ Critical Care Exit And New Policy Hire Might Change The Case For Investing In EW

Edwards Lifesciences recently appointed Niranjan Pai, formerly a director at APCO with prior experience at Ernst & Young, as Director-Government Affairs, while...

Edwards’ Critical Care Exit And New Policy Hire Might Change The Case For Investing In EW

Analyst ratings

67%

of 33 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.